- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.03. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 07.03. | Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.7% - What's Next? | 1 | MarketBeat | ||
| 04.03. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 93 | GlobeNewswire (Europe) | BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| 03.03. | Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate | 1 | Benzinga.com | ||
| 03.03. | Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts | 2 | Benzinga.com | ||
| 28.02. | Praxis Precision Medicines Plunges 39% After Study Termination Recommendation | 4 | RTTNews | ||
| 28.02. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Update on Essential3 and Corporate Update | 170 | GlobeNewswire (Europe) | BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| 28.02. | Praxis Precision Medicines, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
| 28.02. | Praxis Precision Medicines, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 28.02. | Praxis Precision Medicines, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.02. | Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High - Should You Buy? | 2 | MarketBeat | ||
| 11.02. | The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts | 3 | Benzinga.com | ||
| 11.02. | What the Options Market Tells Us About Praxis Precision Medicine | 2 | Benzinga.com | ||
| 11.02. | Deutsche Bank sets $111 target for Praxis Precision shares | 10 | Investing.com | ||
| 04.02. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 100 | GlobeNewswire (Europe) | BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| 29.01. | Praxis Precision Medicines, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts | 1 | Benzinga.com | ||
| 21.01. | Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 8.5% Following Analyst Upgrade | 1 | MarketBeat | ||
| 13.01. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities | 947 | GlobeNewswire (Europe) | Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide... ► Artikel lesen | |
| 23.12.24 | Praxis Precision Medicines files for automatic mixed securities shelf | 3 | Seeking Alpha |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,125 | +1,07 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
| QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| MODERNA | 25,230 | -3,74 % | Moderna-Aktie leicht im Minus (29,9070 €) | Der Anteilsschein von Moderna notiert heute ein wenig leichter. Der jüngste Kurs betrug 32,24 US-Dollar. Für der Anteilsschein von Moderna steht gegenwärtig ein Abschlag von 4,13 Prozent zu Buche. Die... ► Artikel lesen | |
| AMGEN | 288,90 | -0,09 % | Amgen Options Trading: A Deep Dive into Market Sentiment | ||
| NOVAVAX | 5,600 | -5,45 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
| BIOGEN | 122,50 | -3,20 % | Organon buys rights to Biogen's biosimilar targeting Roche's Actemra | ||
| ILLUMINA | 72,35 | -1,39 % | Illumina Announces Board Changes: Scott Gottlieb Appointed Chair, Keith Meister Joins | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), an American biotechnology company, Tuesday has announced changes to its Board of Directors. Scott Gottlieb, MD, who has been a board member since... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 30,700 | -3,15 % | Crispr Therapeutics Aktie: Verliert ihren Kurs? | Der Austritt des operativen Geschäftsführers beim Gentherapie-Unternehmen beunruhigt Investoren und wirft Fragen zur Projektkontinuität im wettbewerbsintensiven Biotech-Sektor auf. Die Finanzmärkte... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,410 | -6,62 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| OCUGEN | 0,604 | -7,57 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 6,126 | -6,50 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with ... | CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,640 | -7,69 % | COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents | Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified... ► Artikel lesen | |
| EDITAS MEDICINE | 1,054 | -2,18 % | Zacks Research Comments on Editas Medicine FY2027 Earnings | ||
| BIOCRYST PHARMACEUTICALS | 6,742 | -2,85 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,066 | -1,90 % | PacBio Appoints Jim Gibson As New CFO | WASHINGTON (dpa-AFX) - Life science technology company PacBio, Inc. (PACB) announced Thursday the appointment of Jim Gibson as the company's new Chief Financial Officer, effective as of his... ► Artikel lesen |
PRAXIS PRECISION MEDICINES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -2,010 (-5,31 %) liegt der Kurs bei 35,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRAXIS PRECISION MEDICINES INC finden Sie auf Wallstreet Online.
